Skip to main content

Advertisement

SpringerLink
Log in

The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin’s lymphoma patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Although a few studies have evaluated the utility of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in treatment-naive T-cell non-Hodgkin’s lymphomas (T-NHLs), a few studies had been conducted to evaluate the role of FDG-PET in patients after treatment. A total of 41 patients with T-NHLs were included who underwent post-autologous stem cell transplantation (ASCT) PET for response assessment in addition to contrast-enhanced CT. The impact of post-ASCT PET on response assessment and predicting prognosis was retrospectively evaluated. Of the 41 patients, 11 (26.8 %) patients showed discordant response between two image modalities (Cohen’s κ = 0.465). The additional PET study actually guides changing the post-ASCT response in six (54.5 %) of these 11 patients. Moreover, positive post-ASCT PET was associated with worse prognosis in event-free survival and overall survival than negative post-ASCT PET (P = 0.003 and P = 0.044, respectively). Excluding four patients in whom further confirmation was not available due to early mortality, in 22 lesions showing discrepancy between two image modalities, 12 lesions were true positive (N = 4) or true negative (N = 8) for PET and ten lesions were false positive (N = 7) or false negative (N = 3). The accuracy for the discrepant lesions was 54.5 % (12 of 22), the overall accuracy for the detected lesions was 76.7 % (33 of 43), and the overall accuracy for patients was 89.2 % (33 of 37). Post-ASCT PET was useful in response assessment after ASCT, and the positive post-ASCT PET result was associated with worse prognosis than the negative post-ASCT PET in patients with T-NHLs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38(3):211–216

    Article  PubMed  CAS  Google Scholar 

  2. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E (2003) Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123(2):282–287

    Article  PubMed  Google Scholar 

  3. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124(2):608–613

    Article  PubMed  Google Scholar 

  4. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 30(2):103–111

    Article  PubMed  CAS  Google Scholar 

  5. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102(1):53–59

    Article  PubMed  CAS  Google Scholar 

  6. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110(6):1361–1369

    Article  PubMed  Google Scholar 

  7. Kassim AA, Mineishi S, Greer JP, McVay N, Koyama T, Chinratanalab W et al (2004) Post-transplant positron emission tomography using fluorine 18-fluoro-deoxyglucose ([18F]FDG-PET) correlates with outcome in patients with aggressive non-Hodgkin’s lymphoma undergoing high dose chemotherapy followed by autologous stem-cell transplantation (HDC/ASCT). ASH Annu Meet Abstr 104(11):906

    Google Scholar 

  8. Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 91(4):490–495

    PubMed  Google Scholar 

  9. Crocchiolo R, Canevari C, Assanelli A, Lunghi F, Tassara M, Stanghellini ML et al (2008) Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 49(4):727–733

    Article  PubMed  CAS  Google Scholar 

  10. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al (2002) Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16(2):260–267

    Article  PubMed  CAS  Google Scholar 

  11. Johnston PB, Wiseman GA, Micallef IN (2008) Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. Bone Marrow Transplant 41(11):919–925

    Article  PubMed  CAS  Google Scholar 

  12. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T et al (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18(10):1685–1690

    Article  PubMed  CAS  Google Scholar 

  13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  14. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578

    Article  PubMed  Google Scholar 

  15. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J-A, Zhuang H et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875–3876

    Article  PubMed  CAS  Google Scholar 

  16. Khong P-L, Pang C, Liang R, Kwong Y-L, Au W-Y (2008) Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87(8):613–621

    Article  PubMed  Google Scholar 

  17. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S et al (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142(5):577–584

    Article  PubMed  Google Scholar 

  18. Bishu S, Quigley JM, Schmitz J, Bishu SR, Stemm RA, Olsasky SM et al (2007) F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 48(8):1531–1538

    Article  PubMed  CAS  Google Scholar 

  19. Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA et al (2008) The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 8(2):94–99

    Article  PubMed  Google Scholar 

  20. Suh C, Kang Y-K, Roh J-L, Kim MR, Kim JS, Huh J et al (2008) Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49(11):1783–1789

    Article  PubMed  Google Scholar 

  21. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK et al (2005) ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin’s lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 35(5):449–454

    Article  PubMed  CAS  Google Scholar 

  22. Jantunen E, Kuittinen T, Nousiainen T (2003) BEAC or BEAM for high-dose therapy in patients with non-Hodgkin’s lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 44(7):1151–1158

    Article  PubMed  CAS  Google Scholar 

  23. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al (2008) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87(1):43–48

    Article  PubMed  CAS  Google Scholar 

  24. Jo JC, Yoon DH, Kim S, Park JS, Park CS, Huh J, Lee SW, Ryu JS, Suh C (2012) Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. Korean J Hematol 47:119–125

    Article  PubMed  CAS  Google Scholar 

  25. Yoshimi A, Izutsu K, Takahashi M, Kako S, Oshima K, Kanda Y et al (2008) Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol 83(6):477–481

    Article  PubMed  Google Scholar 

  26. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L et al (2002) Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29(12):1639–1647

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea

    Byeong Seok Sohn, Dok Hyun Yoon, Kyu Pyo Kim, Shin Kim, Kyung Min Lee, Jung Sun Park, Dae Ho Lee & Cheolwon Suh

  2. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Jin-Sook Ryu & Il Ki Hong

  3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Jooryung Huh

  4. Department of Nuclear Medicine, Kyung Hee University Medical Center, Seoul, South Korea

    Il Ki Hong

  5. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea

    Byeong Seok Sohn

Authors
  1. Byeong Seok Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dok Hyun Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyu Pyo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyung Min Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jung Sun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dae Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin-Sook Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jooryung Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Il Ki Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cheolwon Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheolwon Suh.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 97 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sohn, B.S., Yoon, D.H., Kim, K.P. et al. The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin’s lymphoma patients. Ann Hematol 92, 1369–1377 (2013). https://doi.org/10.1007/s00277-013-1782-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1782-5

Keywords

Search

Navigation